Comparative Pharmacology
Head-to-head clinical analysis: DEXTROSE 5 SODIUM CHLORIDE 0 33 AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXTROSE 5 SODIUM CHLORIDE 0 33 AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER vs MAGNESIUM SULFATE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextrose provides glucose for cellular energy metabolism; sodium chloride corrects electrolyte imbalances; potassium chloride maintains intracellular potassium levels and repolarizes cell membranes.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Intravenous infusion; typical adult maintenance dose is 1000-2000 mL per day at a rate of 50-100 mL/hour, providing 40 mEq of potassium chloride per liter.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
None Documented
None Documented
Dextrose: <1 hour (rapidly metabolized). Sodium/chloride/potassium: not applicable as electrolytes are regulated by homeostatic mechanisms, not eliminated via half-life.
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Dextrose is metabolized to CO2 and water, with <5% excreted unchanged renally. Sodium and chloride are primarily excreted renally (≥90%), with minimal fecal or biliary elimination. Potassium is >90% excreted renally, with minor fecal loss (≤8%).
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Category A/B
Category C
Electrolyte
Electrolyte